By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
Continued maintenance BCG might be considered in BCG-responsive patients with very high-risk NMIBC without adverse clinical and pathologic features. Rather than undergo upfront radical cystectomy, ...
The bacillus Calmette-Guérin (BCG) vaccine nearly halved the risk of progression among patients with non–muscle invasive bladder cancer (NMIBC) compared with transurethral resection of the bladder ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to ...
TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study. The University of Chicago Medicine received approval from the ...
Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback